Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19889980 | 0.73 | SRC (0.47) | SRCEGFR | |
| SCHEMBL19889982 | 0.71 | KHK (0.36) | CSNK1A1CLK4SRCEGFRMAP3K8 | |
| SCHEMBL19889974 | 0.71 | EGFR (0.42) | SRCEGFRMAP3K8CYP11B2 | |
| SCHEMBL25636706 | 0.71 | CYP11B2 (0.35) | CSNK1A1CLK4SRCEGFRMAP3K8 | |
| SCHEMBL19889979 | 0.69 | CYP11B2 (0.39) | CSNK1A1CLK4SRCEGFRMAP3K8 | |
| SCHEMBL19877263 | 0.69 | CYP11B2 (0.35) | CSNK1A1CLK4SRCEGFRMAP3K8 | |
| SCHEMBL23899093 | 0.68 | SRC (0.37) | CSNK1A1CLK4SRCEGFRMAP3K8 | |
| SCHEMBL19889983 | 0.68 | CYP11B2 (0.38) | CSNK1A1CLK4SRCEGFRMAP3K8 | |
| SCHEMBL22301636 | 0.68 | CYP11B2 (0.35) | CSNK1A1CLK4SRCEGFRMAP3K8 | |
| SCHEMBL30721099 | 0.68 | CYP11B2 (0.35) | CSNK1A1CLK4SRCEGFRMAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3496716-B1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3496716-B1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| EP-3496716-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | Merck Sharp & Dohme Corp. (US) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018034918-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018034918-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | CYP27A1, CYP7B1, CYP7A1 | CSNK1A1 1225/4885CLK4 3220/4885SRC 3199/4885 |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | CYP27A1, CYP7B1, SLC10A1 | CSNK1A1 1245/4885CLK4 3095/4885SRC 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.